• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Connect with Us
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

Metabolic

AstraZeneca is pleased to present healthcare professionals with a variety of metabolic resources for your informational purposes.
The educational materials are intended to provide disease-state information that can assist you in forming your own clinical and treatment decisions.

  1. Congress Library
  2. Medications
  3. Disease Education
  4. Continuing Education
  5. Pipeline
  • BYDUREON BCise® (exenatide extended-release) injectable suspension
  • BYDUREON® (exenatide extended-release) for injectable suspension
  • BYETTA® (exenatide) Injection
  • FARXIGA® (dapagliflozin) Tablets
  • KOMBIGLYZE® XR (saxagliptin and metformin HCl extended-release) Tablets
  • ONGLYZA® (saxagliptin) Tablets
  • QTERN® (dapagliflozin and saxagliptin) Tablets
  • SYMLIN® (pramlintide acetate) Injection
  • XIGDUO® XR XR (dapagliflozin and metformin HCI extended-release) Tablets

e-Learning

Navigating an Increasingly Complex Treatment Paradigm in the Management of Type 2 Diabetes: Optimizing Cardiovascular and Renal Outcomes with SGLT2 Inhibitors

National Association of Managed Care Physicians, Inc.

01-Jul-2021 to 01-Aug-2022

1 hour webcast

Learn More

e-Learning

Atherosclerotic Cardiovascular Disease, Heart Failure, and SGLT2 Inhibitors: Insights into Implementing Evidence-Based Treatment Strategies

Voxmedia LLC

01-Sept-2020 to 01-Sept-2022

60-min live PCNA Symposium and 60-min enduring

Learn More

Redirecting...

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am a payer or formulary decision-maker
I am neither (take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2022 AstraZeneca. All rights reserved.

US-69609

Last Updated 11/22

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Privacy Notice

Legal Notice

Cookie Notice

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Pharma Logo

Privacy NoticeLegal NoticeCookie Notice